More Galleries
7 hot businesses to start now It's hard to predict what businesses will take off, but these startup ideas have been drawing tons of interest from entrepreneurs and their customers on Thumbtack.com. More
How will a minimum wage hike hit businesses? Thirteen states increased the minimum wage on Jan. 1, and President Obama supports raising the federal rate to $10.10. 4 small business owners weigh in on how an increase would affect them. More
America's favorite businesses From a science camp for girls to a kombucha brewer, communities around the country voted on their favorite small businesses. These 12 came out on top, each scoring a $250,000 grant from Chase and a trip to Google's headquarters. More

Special Offer
14 of 36
BACK NEXT
A new way to halt seizures
A new way to halt seizures
Christina Li, John Stroncek, Heidi Koschwanez and Vivek Sasikumar
Team name: Cerene Biomedics

School: Duke University, Fuqua School of Business

Team members: Heidi Koschwanez, Christina Li, Carolyn Nohejl, John Stroncek, Vivek Sasikumar

Concept: Cerene Biomedics is working to prevent seizures using a kind of high-tech brain freeze. The Cerene team, comprised of five Duke University graduate students, has developed a business-card-sized thermoelectric cooling device that can be implanted via craniotomy on the neocortical surface of an epileptic's brain. The cooling device would be automatically activated within milliseconds of seizure onset, essentially stopping the seizure before it started by slowing synaptic processes.

Cerene plans to sell the devices directly to hospitals, for around $20,000 each. While most of the 2.7 Americans living with epilepsy wouldn't be prime Cerene customers - the device would be appropriate only for the minority of patients who have a surface-level neocortical seizure focus and for whom medication does not suppress seizures - the Duke team believes that approximately 230,000 epileptic patients in the U.S. could benefit from their device.

Within that market, Cerene hopes for 2% patient adoption rate in the first year and a 20% market share by the fifth year. Getting there won't be easy, however. There are several testing, regulatory and licensing hurdles to overcome before the device can be commercialized - plus the challenge of recruiting patients willing to implant a device in their skull.

Four of Cerene's founders are pursuing doctoral or master's degrees in biomedical engineering at Duke, and the fifth founder is a medicinal chemist in his second year of Duke's MBA program.

Timeline: Cerene Biomedics is seeking seed funding from government programs, epilepsy foundation grants, and angel investors. With that funding it hopes to develop a prototype and conduct efficacy and safety studies over the two years. - Ben Frumin

NEXT: A new tool for finding cancer faster

Last updated May 02 2008: 11:51 AM ET
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.